The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
Pancreatic ductal adenocarcinoma (PDAC) is still difficult to treat due to insufficient methods for early diagnosis and prediction of therapy response. Furthermore, surveillance after curatively intended surgery lacks adequate methods for timely detection of recurrence. Therefore, several molecules...
Saved in:
Main Authors: | Niklas Sturm, Thomas Jens Ettrich, Lukas Perkhofer |
---|---|
Format: | Revisão |
Language: | English |
Published: |
2022
|
Online Access: | https://doi.org/10.3390/cancers14010217 https://www.mdpi.com/2072-6694/14/1/217/pdf?version=1641282367 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
by: Sturm, Niklas, et al.
Published: (2022) -
Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling
by: Ettrich, Thomas J., et al.
Published: (2022) -
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions
by: Niklas Sturm, et al.
Published: (2022) -
Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
by: Hongbeom Kim, et al.
Published: (2020) -
Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
by: Kim, Hongbeom, et al.
Published: (2020)